Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Jesús G. Berdeja et al.|New England Journal of Medicine|2019Cited by 1.7k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, Pieter Sonneveld, David S. Siegel et al.|Leukemia|2011Cited by 721
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).Sham Mailankody, Sandy W. Wong, Andrzej Jakubowiak et al.|Journal of Clinical Oncology|2020Cited by 122
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm studyJames R. Berenson, Regina A. Swift, Ralph V. Boccia et al.|British Journal of Haematology|2006Cited by 83
Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)John Kuruvilla, Mansoor Raza Mirza, Martin Gutierrez et al.|Blood|2013Cited by 30